Home > Oncology > ASCO 2020 > Lung Cancer > ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

Presented By
Prof. Luis G. Paz-Ares, Hospital 12 de Octubre, Spain
Conference
ASCO 2020
Trial
Phase 3, CASPIAN
Featured video: Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study. https://vimeo.com/440629763 The addition of tremelimumab to frontline durvalumab and platinum-based chemotherapy did not demonstrate a statistically significant improvement in overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC), missing the co-primary endpoint of the phase 3 CASPIAN study. Presented by Prof. Luis Paz-Ares (Hospital 12 de Octubre, Madrid, Spain), this was the first report of the third study arm of CASPIAN, in which the investigational CTLA-4 inhibitor tremelimumab was added to PD-L1 checkpoint inhibitor durvalumab on top of standard of care chemotherapy [1]. ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on